Overcoming Product Instability And Improving Yield

Early‑stage API production often focuses on achieving high reaction conversion, but strong conversion does not always translate into acceptable isolated yield. In preclinical programs, unexpected product instability can surface during scale‑up, putting critical timelines—such as toxicology studies—at risk.

By applying complementary analytical tools beyond standard HPLC, an unrecognized degradation pathway was identified during the reaction phase. The product was decomposing under reaction conditions rather than being lost during downstream processing, a distinction with major implications for process control. With this insight, reaction monitoring and quenching strategies were refined to minimize exposure to degrading conditions. Reaction time was shortened, completion closely tracked, and the mixture promptly quenched at the optimal endpoint.

These targeted adjustments resulted in a significant yield improvement and enabled successful production of the required toxicology material. While further redesign was planned for long‑term scalability and stability, the immediate intervention ensured program continuity during a critical preclinical phase.